Supplementary Table 1 | ACR responses at 6 months in trials of biologic therapies and a Syk inhibitor in patients with RA who had inadequate responses to DMARDs

Supplementary Table 1 | ACR responses at 6 months in trials of biologic therapies and a Syk inhibitor in patients with RA who had inadequate responses to DMARDs
Biologic treatment*	Dose	Trial	Number of patients	ACR20 response	ACR50 response	ACR70 response	Reference
Abatacept	10 mg/kg per month	NA	339	60%	36%	16%	Kremer et al. (2003)1
Adalimumab	40 mg every 2 weeks	ARMADA	271	67%	55%	27%	Weinblatt et al. (2003)2
Certolizumab	200 mg every 2 weeks	RAPID 1	982	53%	38%	21%	Keystone et al. (2008)3
Etanercept	25 mg twice a week	NA	234	59%	40%	14%	Moreland et al. (1999)4
Golimumab	50 mg per month	GO-FORWARD	444	60%	38%	18%	Keystone et al. (2009)5
Infliximab	3 mg/kg every 8 wk	ATTRACT‡	428	50%	27%	8%	Maini et al. (1999)6
Rituximab	2 pulses of 1000 mg	DANCER	465	54%	34%	20%	Emery et al. (2006)7
Tocilizumab	8 mg/kg every month	OPTION	622	59%	44%	22%	Smolen et al. (2008)8
Oral Syk inhibitor
Fostamatinib	100 mg twice daily	NA	457	66%	43%	28%	Weinblatt et al. (2010)9
*Biologic agents are presented in alphabetical order. ‡Clinical assessment at 30 weeks. Abbreviation: ACR20/50/70, American College of Rheumatology criteria for 20%/50%/70% improvement; NA, not applicable; Syk, spleen tyrosine kinase.

1. Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T‑cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907–1

2. Weinblatt, M. E. et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35–45 (2003).

3. Keystone, E. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty‑two‑week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319–3

4. Moreland, L. W. et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478–

5. Keystone, E. C. et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO‑FORWARD Study. Ann. Rheum. Dis. 68, 789–

6. Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932–1

7. Emery, P. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390–1

8. Smolen, J. S. et al. Effect of interleukin‑6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987–

9. Weinblatt, M. E. et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303–1